Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06909500

A Digital Intervention (ACT on Vaping App) for Vaping Cessation in Young Adult E-Cigarette Users

This clinical trial evaluates a smartphone application (app) called Acceptance and Commitment Therapy (ACT) on Vaping for helping young adults quit using electronic cigarettes (e-cigarettes). E-cigarettes pose numerous risks, particularly to youth and young adults. Addressing the high prevalence of e-cigarette use by young adults requires effective and accessible treatments to support current users to quit. Research shows this group prefers and benefits from newer methods of treatment delivery such as digital interventions. ACT on Vaping is a digital therapeutic intended to deliver behavioral therapy to young adults who vape to motivate and support abstinence from all nicotine and tobacco products. The app contains sessions that promote awareness of cues that trigger tobacco use and teach skills for responding to these triggers in a way that is tailored for the participant's readiness to quit. Receiving access to the ACT on Vaping app may be effective in helping young adults quit vaping.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Nicotine Dependence Chemically-Induced Disorders Mental Disorders Substance-Related Disorders Tobacco Use Disorder Tobacco-Related Carcinoma

Age range

18 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

Location status: Recruiting

Location contact

Jaimee Heffner, PhD

CONTACT

[email protected]

206-667-7314

Jaimee Heffner, PhD

PRINCIPAL_INVESTIGATOR

About this study

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I: Participants use the ACT on Vaping app (Version A) and receive a text messaging program to motivate and support quitting. Participants also receive incentivized text message check-ins at 2 weeks, 2 months, and 4 months to assess their vaping status.

ARM II: Participants use the ACT on Vaping app (Version B) and receive incentivized text message check-ins at 2 weeks, 2 months, and 4 months to assess their vaping status.

After completion of study intervention, participants are followed up at 3, 5.5, and 6 months.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-30
  • Current weekly user of e-cigarette product(s) for the last 30 days
  • Has a smartphone; either an Android (running version 12 or higher) or iPhone (running iOS version 17 or higher, iPhone 11 or more recent)
  • Experience downloading and using one or more apps on their smartphone
  • Have a mobile data plan and/or access to WiFi to support the use of the ACT on Vaping app
  • Has access to text messaging
  • Has an email address
  • United States (US) resident, with a US mailing address
  • Willing to complete all study procedures
  • Comfortable reading and writing in English

Exclusion criteria

  • Currently using other tobacco cessation treatments at the time of screening, including pharmacotherapy or behavioral support (note: use of these treatment is allowable during trial participation)
  • Member of the same household as another research participant
  • Currently in prison
  • Google voice number as sole phone number, due to its association with fraudulent study entry attempts
  • Is ineligible per fraud prevention protocol
  • Employees/family of investigator or study center

Treatment and study plan

Smartphone App

Behavioral

Receive access to the ACT on Vaping app

Other names: ACT on Vaping (Version A)

Text message

Other

Receive incentivized text messages to access vaping status

Other names: SMS Text

Survey Administration

Other

Ancillary studies

Primary outcomes

  1. Cotinine-confirmed 30-day point prevalence abstinence from all nicotine and tobacco

    Time frame: At 6 months post-randomization

    Biochemically confirmed 30-day abstinence from all nicotine and tobacco (excluding Food and Drug Administration [FDA]-approved pharmacotherapies). Will be assessed in each individual and summarized within each group as a proportion.

Secondary outcomes

  1. Self-reported 30-day point prevalence abstinence from vaping

    Time frame: At 3 months post-randomization

    Proportion of participants self-reporting 30-day abstinence from vaping. Will be assessed in each individual and summarized within each group as a proportion. The proportion of "success" will be compared between groups using logistic regression.

  2. Self-reported 30-day point prevalence abstinence from vaping

    Time frame: At 6 months post-randomization

    Proportion of participants self-reporting 30-day abstinence from vaping. Will be assessed in each individual and summarized within each group as a proportion. The proportion of "success" will be compared between groups using logistic regression.

  3. Cotinine-confirmed 7-day point prevalence abstinence from all nicotine and tobacco

    Time frame: At 3 months post-randomization

    Biochemically confirmed 7-day abstinence from all nicotine and tobacco (excluding FDA-approved pharmacotherapies). Will be assessed in each individual and summarized within each group as a proportion. The proportion of "success" will be compared between groups using logistic regression.

  4. Number of 24-hour quit attempts

    Time frame: Baseline to 3 months post-randomization

    Number of times between baseline and 3-month follow-up that participant stopped using all nicotine and tobacco (excluding FDA-approved pharmacotherapies) for 24 hours or longer. Will be assessed in each individual and summarized within each group as a continuous variable and analyzed using linear regression.

  5. Change in readiness to quit using electronic cigarettes (e-cigarettes) on the Contemplation Ladder

    Time frame: Baseline to 3 months post-randomization

    Self-reported motivation to quit smoking e-cigarettes (Contemplation Ladder), rated 1-10. Higher scores indicate greater motivation to quit (i.e., high [> 5] versus low [5 or less]). Will be assessed in each individual and summarized within each group as a change score and analyzed using linear regression.

Study contacts

Contact information is provided by the study sponsor or research team.

Jaimee Heffner, PhD

CONTACT

[email protected]

206-667-7314

Sponsors and collaborators

Lead sponsor

Fred Hutchinson Cancer Center

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

ACT on Vaping: Digital Therapeutic for Young Adult Vaping Cessation

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Apr 3, 2025
Registry last updated
Jul 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.